FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 139 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Understanding the Risk of Second Cancers After CAR T-Cell Therapy August 13, 2024 Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit... June 17, 2021 This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... May 22, 2023 Load more HOT NEWS Foster Teen With A Passion For Painting Is Patiently Waiting For... One year on: How has COVID-19 affected cancer services? Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD...
